Daniel T Merrick
Overview
Explore the profile of Daniel T Merrick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1506
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gibb M, Reinert A, Schedin T, Merrick D, Brown J, Bauer A
Toxicol Sci
. 2025 Feb;
PMID: 39992237
Formaldehyde (FA) is a common chemical linked to respiratory problems such as airway hyperresponsiveness and pulmonary inflammation. Due to its toxicological effects and ease of mass production, FA is also...
2.
Faupel-Badger J, Kohaar I, Bahl M, Chan A, Campbell J, Ding L, et al.
Nat Rev Cancer
. 2024 Oct;
24(11):792-809.
PMID: 39354069
The term 'precancer' typically refers to an early stage of neoplastic development that is distinguishable from normal tissue owing to molecular and phenotypic alterations, resulting in abnormal cells that are...
3.
Gindra R, Zheng Y, Green E, Reid M, Mazzilli S, Merrick D, et al.
Am J Pathol
. 2024 Apr;
194(7):1285-1293.
PMID: 38588853
Bronchial premalignant lesions (PMLs) precede the development of invasive lung squamous cell carcinoma (LUSC), posing a significant challenge in distinguishing those likely to advance to LUSC from those that might...
4.
Blomberg R, Sompel K, Hauer C, Smith A, Pena B, Driscoll J, et al.
Adv Healthc Mater
. 2023 Nov;
13(4):e2302246.
PMID: 37953708
Lung cancer is the leading global cause of cancer-related deaths. Although smoking cessation is the best prevention, 50% of lung cancer diagnoses occur in people who have quit smoking. Research...
5.
Miller Y, Ghosh M, Merrick D, Kubala B, Szabo E, Bengtson L, et al.
Front Oncol
. 2023 Sep;
13:1204726.
PMID: 37711198
Introduction: Iloprost, a prostacyclin analog, has lung cancerpreventive activity in preclinical models and improved dysplasia in former smokers in a phase IIb trial. Oral iloprost is currently unavailable. We performed...
6.
Assante A, Lkhagvadorj K, Clambey E, Danhorn T, Merrick D, Keith R, et al.
Am J Respir Crit Care Med
. 2023 Aug;
208(8):903-905.
PMID: 37639330
No abstract available.
7.
Hill W, Lim E, Weeden C, Lee C, Augustine M, Chen K, et al.
Nature
. 2023 Apr;
616(7955):159-167.
PMID: 37020004
A complete understanding of how exposure to environmental substances promotes cancer formation is lacking. More than 70 years ago, tumorigenesis was proposed to occur in a two-step process: an initiating...
8.
Blomberg R, Sompel K, Hauer C, Pe A B, Driscoll J, Hume P, et al.
bioRxiv
. 2023 Mar;
PMID: 36993773
Lung cancer is the leading global cause of cancer-related deaths. Although smoking cessation is the best preventive action, nearly 50% of all lung cancer diagnoses occur in people who have...
9.
Kleczko E, Hinz T, Nguyen T, Gurule N, Navarro A, Le A, et al.
NPJ Precis Oncol
. 2023 Feb;
7(1):15.
PMID: 36739466
Lung cancers bearing oncogenic EML4-ALK fusions respond to targeted tyrosine kinase inhibitors (TKIs; e.g., alectinib), with variation in the degree of shrinkage and duration of treatment (DOT). However, factors that...
10.
Kleczko E, Le A, Hinz T, Nguyen T, Navarro A, Hu C, et al.
Cancer Lett
. 2023 Jan;
556:216062.
PMID: 36657561
Lung cancers bearing oncogenically-mutated EGFR represent a significant fraction of lung adenocarcinomas (LUADs) for which EGFR-targeting tyrosine kinase inhibitors (TKIs) provide a highly effective therapeutic approach. However, these lung cancers...